Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer
To evaluate the tolerability, safety, pharmacokinetic characteristics and immunogenicity of Almonertinib combined with SHR-1701 in relapsed or advanced NSCLC To evaluate the efficacy of Almonertinib combined with SHR-1701 in the first-line treatment of relapsed or advanced NSCLC
Relapsed or Advanced Non-small Cell Lung Cancer
DRUG: Almonertinib combined with SHR-1701|DRUG: Almonertinib
Dose limiting toxicity （Phase Ib）, 21 days after the first dose|The incidence and severity of ≥ grade 3 treatment-related adverse events (TRAE) and serious adverse events (TRSAE) in the combination of two drugs （Phase Ib）, from the time when all informed subjects signed the informed consent to the end of the safety follow-up period|PFS rate at 12 months, Progression-Free-Survival, defined as the time from randomization to the first occurrence of disease progression or death from any cause, whichever occurs first., 12 months after the first medication for the last subject
Adverse Events and Serious Adverse Events, up to 3 years|Proportion of dose pauses, dose downgrades and dose terminations due to study-drug related toxicities during the trial, up to 3 years|ORR, up to 3 years|DCR, Disease Control Rate, determined using RECIST v1.1 criteria, up to 3 years|DoR, Duration of Response, determined using RECIST v1.1 criteria, up to 3 years|DepOR, Depth of tumor remission, determined using RECIST v1.1 criteria, up to 3 years|PFS, Progression-Free-Survival, determined using RECIST v1.1 criteria, up to 3 years|OS, OS is the time interval from the date of randomization to death due to any reason or lost of follow-up, up to 5 years
To evaluate the tolerability, safety, pharmacokinetic characteristics and immunogenicity of Almonertinib combined with SHR-1701 in relapsed or advanced NSCLC To evaluate the efficacy of Almonertinib combined with SHR-1701 in the first-line treatment of relapsed or advanced NSCLC